Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
Volume 0.18M
Average 0.05M
COEP Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Coeptis Therapeutics, Inc.NASDAQ: COEP
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $1.42M rose 136.9% year over year, ahead of the +13.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 562.1% from the prior quarter.
Context
- Stock-based compensation amounted to 89.2% of revenue in FY2025.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +136.9% holds above the trailing-twelve-month pace of +13.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 1.22M USD
- Year-over-year change
- +10.0%
- 4-year CAGR
- -10.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.22M | +10.0% |
| FY2024 | 2024-12-31 | 1.1M | +131.4% |
| FY2023 | 2023-12-31 | 477.5K | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 1.9M | — |
Stock-Based Compensation vs competitors
How COEP compares with its peers on the latest reported figures
- COEP's LTM Mar 2026 stock-based compensation of $1.82M is the 8th largest of the 9 companies compared; the peer median is $4.53M.
- Its year-over-year change of +13.4% is the 3rd highest of 9, against a peer median of -29.9%.
- Stock-based compensation amounts to 128.8% of revenue for COEP, versus a peer median of 13.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $4.27B | +453006.6% | — | — |
| LTM Mar 2026 | $13.5M | -20.7% | -26.5% | 8.9% | |
| LTM Mar 2026 | $5.86M | -50.8% | -13.8% | — | |
| LTM Mar 2026 | $5.14M | -37.3% | +4.9% | 1543.3% | |
| LTM Mar 2026 | $3.92M | -52.4% | — | — | |
| LTM Mar 2026 | $3.45M | -44.6% | -20.7% | 10.6% | |
| LTM Mar 2026 | $2.63M | -22.6% | -21.7% | — | |
| LTM Mar 2026 | $1.82M | +13.4% | — | 128.8% | |
| LTM Mar 2026 | $367K | +43.4% | -60.2% | 16.0% | |
| Peer median (excluding COEP) | $4.53M | -29.9% | -21.2% | 13.3% | |
Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.45M) | (37.57M) | (21.27M) | (10.88M) | (11.92M) |
| Depreciation & Amortization | 447.41K | 1M | 1.04M | 1.04M | 1.22M |
| Deferred Income Tax | 5.34M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.9M | 0 | 477.5K | 1.1M | 1.22M |
| Change in Working Capital | (2.98M) | (550.34K) | 1.73M | (125.26K) | (1.46M) |
| Accounts Receivables | 21.79K | (8.08K) | (30.9K) | (234.74K) | (7.35K) |
| Inventory | (422.02K) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.58M) | (35.07K) | 1.32M | (149.94K) | (381.01K) |
| Other Working Capital | (1M) | (507.19K) | 437.31K | 259.42K | (1.07M) |
| Other Non-Cash Items | 4.26M | 33.25M | 10.79M | 2.21M | 2.34M |
| Operating Cash Flow | (4.49M) | (3.88M) | (7.24M) | (6.65M) | (8.6M) |
| Capital Expenditures | (1.75M) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.75M) | 0 | 0 | 0 | 0 |
| Debt Repayment | (1.62M) | (2.42M) | (575K) | 1.2M | 771.25K |
| Common Stock Issued | 10.14M | 3.27M | 5.29M | 100K | 12.97M |
| Common Stock Repurchased | (247.17K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (50.9K) | 4.63M | 200K | 500K | 0 |
| Financing Cash Flow | 8.22M | 5.49M | 4.92M | 5.71M | 13.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.98M | 1.61M | (2.32M) | (936.25K) | 5.14M |
| Free Cash Flow | (6.24M) | (3.88M) | (7.24M) | (6.65M) | (8.6M) |
Coeptis Therapeutics, Inc.
NASDAQ:COEP
Intrinsic Alpha fair value
Locked
Current Price
$14.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.